NFKB1 and neoplasm: MiRNA-126a was shown to target the NF-κB inhibitor, IκBα, leading to canonical NF-κB activation thereby contributing to pathogenesis of ulcerative colitis [148], but paradoxically was shown to act as tumor suppressor for colon cancer [149].